FDA Warns Apotex Management To Demand Quality, Meet Specs
Executive Summary
Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.
You may also be interested in...
Warning Letters Special Report: The Decline And Fall Of Morton Grove Pharmaceuticals
It was bad enough that out-of-specification investigations were hugely inadequate, but the firm’s response to the FDA’s findings was even worse.
Some Pointers From The US FDA On How To Conduct Better Out-Of-Spec Investigations
Industry is still having major problems in this area despite the FDA's exhaustive 2006 OOS guidance.
Apotex Withdraws 31 ANDAs After Failing To Ensure Data Integrity At Two Indian Manufacturing Plants
Persistent data integrity and quality unit failures at two Apotex plants in Bangalore, India, led to wholesale US market withdrawals by the Canadian generic drug manufacturer.